Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-18 4:54 pm Unchanged | 2022-02-11 | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 118,315 6.200% | 0 (Unchanged) | Filing History |
| 2022-02-14 6:33 pm Purchase | 2021-12-31 | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | Armistice Capital, LLC | 31,640 9.990% | 31,640 (New Position) | Filing History |
| 2022-02-14 4:07 pm Sale | 2021-12-31 | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CAXTON CORP | 115,724 6.000% | -91 (-0.08%) | Filing History |
| 2022-02-14 3:32 pm Purchase | 2021-12-31 | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | THE GOLDMAN SACHS GROUP, INC. GS | 150,349 6.100% | 150,349 (New Position) | Filing History |
| 2022-02-14 1:57 pm Purchase | 2021-12-31 | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CREDIT SUISSE AG | 93,830 4.950% | 118 (+0.13%) | Filing History |
| 2022-02-11 4:48 pm Purchase | 2021-12-31 | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 118,315 4.500% | 2,500 (+2.16%) | Filing History |
| 2022-01-10 1:15 pm Unchanged | 2021-12-16 | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 20.400% | 0 (Unchanged) | Filing History |